Specific uptake of Aβ1-40 in rat brain occurs in astrocyte, but not in microglia
Abstract
In the brain of a patient with Alzheimer's disease, beta amyloid peptide (Abeta) is thought to be taken up by glial cells such as astrocyte and microglia to be degraded. However, it is unclear whether the Abeta is absorbed by astrocyte or microglia. The purpose of our study is to determine which type of glial cell, astrocyte or microglia, can take up Abeta. Beta amyloid 1-40 (Abeta1-40) was directly infused into the frontal cortex or hippocampus for 14 days. Dual-labeling immunohistochemistry for Abeta1-40 with an astrocytic (GFAP) or microglial (CD11b) marker was performed to examine co-localization of Abeta1-40 and glial markers. In the Abeta1-40 infused site, immunoreactivity of Abeta1-40 was observed only in astrocytes, not in microglia. In addition, Abeta40-1, a reverse peptide of Abeta1-40, was not taken up by astrocytes. These results suggested that the astrocyte-specific uptake of Abeta occurred in the rat brain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Astrocytes are capable of taking up amyloid peptides.
“Several studies have shown that astrocytes are capable of taking up amyloid peptides (Funato et al., 1998; Matsunaga et al., 2003; Nagele et al., 2003; Lasagna-Reeves and Kayed, 2011), and in vitro this ability was restricted to adult astrocytes (al-Ali and al-Hussain, 1996; Wyss-Coray et al., 2003; Koistinaho et al., 2004; Pihlaja et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Matsunaga et al., 2003
The citation lists haven’t been fetched yet
References 10 · Cited by 36
- Authors
- Matsunaga, W., Shirokawa, T., & Isobe, K.
- Corresponding author
- Shirokawa, Tetsuya
- ORCID
- Matsunaga, Wataru
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 342
- Issue
- 1-2
- Pages
- 129-131
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W1969844849
- Cited by
- 36
- References
- 10
- Citations by year
- 2026: 1 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Aβ40, astrocytes, microglia, glial cells, Alzheimer's disease, glial fibrillary acidic protein, CD11b, frontal cortex, hippocampus
- MeSH terms
- Animals, Astrocytes, Frontal Lobe, Hippocampus, Immunohistochemistry, Male, Peptide Fragments, Rats, Inbred F344, Amyloid beta-Peptides, Microglia, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
